Opko Licenses Protein Biomarker Panel for Prostate Cancer to IHT | GenomeWeb

NEW YORK (GenomeWeb News) – Opko Health today announced it has granted UK-based International Health Technology the rights to offer a novel panel of protein biomarkers and an associated algorithm in parts of Europe for the detection of prostate cancer.

Under the terms of the deal, IHT will offer the biomarker panel in laboratory settings in the UK, Ireland, Sweden, and Denmark. Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.